Weekly Funding Opportunities

[med-Research]

NSF Dear Colleague Letter: Tool Development for Cell Biology (Tools4Cells)<https://www.nsf.gov/pubs/2021/nsf21057/nsf21057.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click>
As scientists’ abilities to open new frontiers in cell biological research continue to be limited by current technologies, there is still a need for the development of new tools and methods to advance our understanding of cells, especially using interdisciplinary approaches that can leverage advances in other fields and apply them to cell biology. Technological advancements have had a profound and catalytic influence on the field of cell biology, either through the application of existing technologies to the study of cellular processes in new and creative ways, or through the development of novel technologies to study areas not previously possible. Relatively recent examples of such advances include: methods of molecular dynamics simulations to study membrane protein signal transmission; gene-editing technologies such as CRISPR/Cas9 applied to probe gene localization; development of new single molecule fluorescence/microscopy techniques to enable in vivo single cell dynamic measurements; single cell sequencing; and the application of cryo-EM and x-ray free electron lasers to the study of protein structure and dynamics. The purpose of this Dear Colleague Letter (DCL) is to encourage submission of proposals to develop novel tools and methods that improve scientists’ abilities to manipulate, control, analyze, or measure critical aspects of cells and their functions in order to open new areas of study in cell biology. Proposals for new tools or methods developments in cell biology can include, but are not limited to the general areas of bioinformatics, instrumentation, or laboratory or field-based research methods. Proposals should be submitted to one of two Divisions in the Directorate for Biological Sciences (BIO) depending on the range of applicability of the tool or method and its connection to a specific research question rather than a general topical area. The research cluster and program within the two BIO divisions that seek proposals in this area are:

  *   Cellular Dynamics and Function Cluster in BIO’s Division of Molecular and Cellular Biology (MCB) if the proposed tool or method addresses a specific research question or hypothesis defined by and to be used by an individual user or group of researchers. Such a project would be evaluated on the importance of the research question or hypothesis and the potential of the tool or method to improve scientists’ ability to study cells or their function related to the question or hypothesis. In addition, for some efforts, the research community is encouraged to take risks in exploring new tools or methods with the potential to change understanding of how cells work.
  *   Infrastructure Innovation for Biological Research Program in BIO’s Division of Biological Infrastructure (DBI) if the proposed tool or method is applicable to a broad class of biological research questions or topics and will meet the needs of a well-defined community of researchers. Such a project would be evaluated on its responsiveness to a well-defined research question in BIO, the specific BIO-funded research community that would benefit, a clear demonstration of how the innovation represents an advance over currently available tools or methods, and the quality of the project management description. Although this DCL is encouraging submissions related to cell biology, this program and all other DBI programs invite proposals on any area of biology that fit within its guidelines.
Proposals responsive to this DCL should be submitted as follows based on the above criteria:

  *   Cellular Dynamics and Function Cluster<https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504861&org=MCB&from=home> via the MCB core solicitation (currently NSF 21-509<https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf21509>). However, for the projects that are “high-risk/high-payoff”, investigators should consider the Early-Concept Grants for Exploratory Research (EAGER) type of proposal which allows requests for up to $300,000 over two years. Specific instructions for preparation and submission of EAGER proposals can be found in Chapter II.E.2 of the NSF Proposal & Award Policies & Procedures Guide<https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20001> (PAPPG).
  *   Infrastructure Innovation for Biological Research Program<https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505459&org=DBI&from=home> via the DBI solicitation (currently NSF 21-502<https://www.nsf.gov/publications/pub_summ.jsp?WT.z_pims_id=505459&ods_key=nsf21502>).
Proposals may be submitted at any time. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor.

Michael J. Fox Foundation: Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research<https://www.michaeljfox.org/grant/promoting-diversity-equity-and-inclusion-parkinsons-disease-research?pn_cid=pn-a1b1R000009f2O3.>
The Michael J. Fox Foundation seeks applications with the potential to increase knowledge about Parkinson’s disease in populations that have been excluded from or underrepresented in research. Though no definitive evidence exists that the incidence, morbidity, or mortality of Parkinson’s disease (PD) varies between socioeconomic and ethnic groups, data on traditionally underrepresented groups is either sparse or nonexistent. This request for applications to promote diversity, equity and inclusion in Parkinson’s research is open to proposals that will increase inclusivity and broaden our understanding of PD. Such projects will help accelerate the discovery of strategies for reducing risk and developing treatments for all people. Applicants may request budgets starting from $50,000 up to $400,000, depending on the scope of work for 18 to 36 months. Applications should focus on studies in underrepresented populations around one or more of the following Parkinson’s areas:

  *   Disease burden: Research toward robust estimates of PD incidence and/or prevalence
  *   Risk and pathology: Diagnostic, biomarker, and/or pathological evaluations to better understand Parkinson’s risk and pathology, and discern how they intersect with the social determinants of health and structural discrimination
  *   Assessments: Evaluation of assessment procedures across different cultures and differential response to treatment
  *   Clinical course: Investigation of how Parkinson’s disease progresses in different populations and likelihood of milestones for advanced disease such as cognitive impairment, refractory motor symptoms and loss of independence
  *   Access to care: Exploration of structural barriers that prevent access to neurology evaluations and care, and access to/uptake of device-aided therapies
Pre-proposals due April 21, 2021. Med-RA deadline to receive draft documents: April 8.

HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-016.html>
The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-015.html> HEAL Initiative: Team Research – for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.
Due April 27, 2021; June 22, 2021; October 13, 2021; June 9, 2022; October 11, 2022; June 9, 2023; and October 10, 2023. Med-RA deadline to receive draft documents for April 27, 2021 due date: April 14.

Congressionally Directed Medical Research Programs
Autism Research Program<https://cdmrp.army.mil/funding/arp>
Clinical Trial Award
Pre-application: May 3, 2021. Invited full application: August 5, 2021.
Idea Development Award
Pre-application: May 3, 2021. Invited full application: August 5, 2021.
Clinical Translational Research Award
Pre-application: May 3, 2021. Invited full application: August 5, 2021.
Career Development Award
Pre-application: May 3, 2021. Invited full application: August 5, 2021.
Med-RA deadline to receive draft documents for the above pre-applications: April 20.
Peer Reviewed Cancer Research Program<https://cdmrp.army.mil/funding/prcrp>
FY 2021 topic areas: bladder cancer; blood cancers; brain cancer; cancers associated with the use of beryllium; colorectal cancer; endometrial cancer, esophageal cancer; germ cell cancers; head and neck cancers; liver cancer; lymphoma, mesothelioma, and metastatic cancers; neuroblastoma, pediatric, adolescent, and young adult cancers; pediatric brain tumors, stomach cancer; sarcoma; thyroid cancer; and the link between scleroderma and cancer.
Behavioral Health Science Award
Pre-application (required letter of intent): July 29. Full application: August 18.
Career Development Award - Fellow Option
Pre-application (required letter of intent): July 29. Full application: August 18.
Med-RA deadline to receive draft documents for the above full applications: July 19.
Idea Award
Pre-application: May 20. Invited full application: September 8.
Impact Award
Pre-application: May 20. Invited full application: September 8.
Med-RA deadline to receive draft documents for the above pre-applications: May 10.
Translational Team Science Award
Pre-application (required letter of intent): July 29. Full application: August 18.
Med-RA deadline to receive draft documents for full application: July 19.
Peer Reviewed Medical Research Program<https://cdmrp.army.mil/funding/prmrp>
FY 2021 topic areas: arthritis, burn pit exposure, congenital heart disease, diabetes, dystonia, eating disorders, emerging viral diseases, endometriosis, epidermolysis bullosa, familial hypercholesterolemia, fibrous dysplasia, focal segmental glomerulosclerosis, food allergies, Fragile X, frontotemporal degeneration, hemorrhage control, hepatitis B, hydrocephalus, hypertension, inflammatory bowel diseases, malaria, metals toxicology, mitochondrial disease, myalgic encephalomyelitis / chronic fatigue syndrome, myotonic dystrophy, non-opioid therapy for pain management, nutrition optimization, pathogen-inactivated blood products, peripheral neuropathy, plant-based vaccines, platelet-like cell production, polycystic kidney disease, pressure ulcers, pulmonary fibrosis, respiratory health, rheumatoid arthritis, sleep disorders and restriction, suicide prevention, sustained release drug delivery, vascular malformations, women’s heart disease.
Clinical Trial Award
Pre-application: May 13. Invited full application: August 26.
Med-RA deadline to receive draft documents for pre-application: May 3.
Discovery Award
Pre-application (required letter of intent): April 29. Full application: May 13.
Med-RA deadline to receive draft documents for full application: May 3.
Focused Program Award
Pre-application: May 13. Invited full application: August 26.
Med-RA deadline to receive draft documents for pre-application: May 3.
Investigator Initiated Research Award
Pre-application: April 28. Invited full application: September 2.
Med-RA deadline to receive draft documents for pre-application: April 15.
Technology / Therapeutic Development Award
Pre-application: April 28. Invited full application: September 2.
Med-RA deadline to receive draft documents for pre-application: April 15.
Tick-Bourne Disease Research Program<https://cdmrp.army.mil/funding/tbdrp.aspx>
Career Development Award
Pre-application: May 26. Invited full application: August 27.
Idea Development Award
Pre-application: May 26. Invited full application: August 27.
Med-RA deadline to receive draft documents for the above pre-applications: May 13.

Gordon and Betty Moore Foundation: Development of Clinical Quality Measures to Improve Diagnosis<https://moore-patientcare.smapply.io/prog/request_for_proposals/>
In November 2018, the Moore Foundation announced its Diagnostic Excellence Initiative<https://www.moore.org/article-detail?newsUrlName=the-moore-foundation-invests-$85-million-to-improve-diagnostic-performance>, which aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes, and save lives. According to the foundation, twelve million Americans experience a diagnostic error each year, with diagnostic errors playing a role in an estimated 40,000 to 80,000 deaths annually in the United States. In other words, there is an urgent need to improve diagnosis; however, without an awareness of baseline performance and standards against which to compare performance, there is no way to measure improvement or to gauge the results of interventions. Despite a lengthy and growing list of clinical quality measures in health care, few existing measures address diagnostic performance specifically. The challenge of finding meaningful clinical measures for diagnosis reflects the complexity of the diagnostic process. To help address the problem, grants of up to $500,000 over eighteen months will be awarded to support the development of innovative clinical quality measures that promote excellence in diagnosis of three categories of disease that comprise the most common and most harmful diagnostic errors, acute vascular events (such as stroke and myocardial infarction), infections (such as sepsis and pneumonia), and cancer (such as lung and colorectal cancer). The expected work requires two interlinked activities: 1) development of the rationale for a measure; and 2) operationalizing the measure into an algorithm.
Due May 10, 2021. Med-RA deadline to receive draft documents: April 27.

Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-005.html>
The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:
Courses for Skills Development: For example, advanced courses in a specific discipline or research area, clinical procedures for research, or specialized research techniques.
This FOA is to support courses for skills development in cross-cutting methodologies and analytics that are needed to advance behavioral and social sciences research (BSSR) but are not well addressed by existing educational programs widely available to the BSSR community. Short courses supported by this FOA should develop, implement, evaluate and disseminate education and training focused on innovative methods for BSSR. Methodological domains of focus include but are not limited to innovative data collection methodologies and analytic techniques, analysis and linking of big data, or needed but underutilized designs to advance research across the translational spectrum.
Due June 4, 2021 (non-AIDS) and September 7, 2021 (AIDS). Med-RA deadline to receive draft documents for June 4, 2021 due date: May 24.

Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 / R01 Clinical Trial Optional)
R21<https://grants.nih.gov/grants/guide/pa-files/PAR-21-176.html>
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-21-175.html>
A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing.
Standard dates apply. Expires May 8, 2024. Med-RA deadline to receive draft documents for June 5, 2021 R01 standard date: May 24; and June 16, 2021 R21 standard date: June 3.

Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-167.html>
This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs’ (ORIP) trans-NIH mission<https://orip.nih.gov/>. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.
Standard dates apply. Expires May 8, 2024. Med-RA deadline to receive draft documents for June 16, 2021 standard date: June 3.

High-Priority Behavioral and Social Research Networks in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (R24 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-012.html>
This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure via networks for behavioral and social research on Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD); attract new researchers into behavioral and social research on AD/ADRD; infuse a focus on health disparities into AD/ADRD research; and address ongoing needs for harmonization and biomarker collection in large population panel studies to support AD/ADRD research as recommended by the 2019 BSR NACA Review<https://www.nia.nih.gov/sites/default/files/2020-02/2019-BSR-Review-Committee-Report-508.pdf>. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: decision neuroscience and aging; measurement for dementia care in home and community-based services; the dementia care workforce; and education and AD/ADRD.
Due June 23, 2021. Med-RA deadline to receive draft documents: June 10.

High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-013.html>
This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure for life course research on aging; attract new researchers in aging; infuse a focus on health disparities into aging research; and address ongoing needs for harmonization and biomarker collection in large population panel studies, as recommended by the 2019 BSR NACA Review<https://www.nia.nih.gov/sites/default/files/2020-02/2019-BSR-Review-Committee-Report-508.pdf>. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: midlife reversibility of biobehavioral risk associated with early life adversity; harmonization of Health and Retirement Study international aging studies; biomarker collection in population studies; and innovation in longitudinal aging studies.
Due June 23, 2021. Med-RA deadline to receive draft documents: June 10.

Data Science: Infectious and Immune-mediated Diseases (R21 / U01 Clinical Trial Not Allowed)
Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-035.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge.
Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-020.html>
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications.
Due July 2, 2021; February 17, 2022; July 1, 2022; February 17, 2023; and July 6, 2023. Med-RA deadline to receive draft documents for July 2, 2021 due date: June 21.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3 / UH3 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-163.html>
The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.
Due August 10, 2021; February 9, 2022; August 9, 2022; February 9, 2023; August 9, 2023; and February 9, 2024 plus standard AIDS dates through May 7, 2024. Med-RA deadline to receive draft documents for August 10, 2021 due date: July 28.

Primals Research Awards: Intriguing for Social, Behavioral, and Psychology Researchers<https://ppc.sas.upenn.edu/sites/default/files/PrimalsResearchAwardsRFP.pdf>
The University of Pennsylvania Positive Psychology Center, with support from the Templeton Religion Trust, is pleased to announce the Primals Research Awards. Our goal is to promote new empirical research exploring how primal world beliefs(‘primals’) are formed, maintained, change, or influence nontrivial outcomes or psychological processes. As recently introduced(Clifton et al., 2019; https://tinyurl.com/y4m62r7k), primals are basic perceptions of the general character of the world as a whole, such as the world is dangerous and the world is interesting, that correlate with many behaviors and wellbeing-related variables. We are awarding one$250,000 award and two $125,000 awards that will be administered over 24 months(July1, 2022 to June30,2024) to Principal Investigators proposingto examine primals from any of the following eight disciplinary perspectives: Clinical Psychology, Positive Psychology, Health Psychology, Organizational Psychology, Political Psychology, Personality Psychology, Social Psychology, and Developmental Psychology.
LOI due September 26, 2021. Med-RA deadline to receive draft documents: September 14.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210326/e5fd57db/attachment.html>